Epigenetic drugs and psychedelics as emerging therapies for alcohol use disorder: insights from preclinical studies.
Fahd François Hilal, Jérôme Jeanblanc, Chloé Deschamps, Mickaël Naassïla, Olivier Pierrefiche, Sami Ben Hamida
Journal of neural transmission (Vienna, Austria : 1996) May 1, 2024 DOI: 10.1007/s00702-024-02757-3 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Population | Animal models |
| Topics | Addiction Neuroplasticity Psychedelic-assisted therapy |
| Keywords | Animal models Epidrugs Psychedelics |
| Citations | 8 |
| Key findings | Psychedelics and epidrugs may share common and complementary mechanisms of action, offering an opportunity for exploring synergies in treating alcohol use disorder. |
Abstract
Alcohol use disorder (AUD) is a public health issue that affects millions of people worldwide leading to physical, mental and socio-economic consequences. While current treatments for AUD have provided relief to individuals, their effectiveness on the long term is often limited, leaving a number of affected individuals without sustainable solutions. In this review, we aim to explore two emerging approaches for AUD: psychedelics and epigenetic drugs (i.e., epidrugs). By examining preclinical studies, different animal species and procedures, we delve into the potential benefits of each of these treatments in terms of addictive behaviors (alcohol drinking and seeking, motivation to drink alcohol and prevention of relapse). Because psychedelics and epidrugs may share common and complementary mechanisms of action, there is an exciting opportunity for exploring synergies between these approaches and their parallel effectiveness in treating AUD and the diverse associated psychiatric conditions.